Novel 3-Cycloaminoindole Compounds as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.
ACS Med Chem Lett January 4, 2025 DOI: 10.1021/acsmedchemlett.4c00615 via PubMed Central
Summary
AI-generated from the abstractThe text describes a class of novel chemical compounds, 3-cycloaminoindoles, that act as serotonergic psychedelic agents. These compounds are proposed for potential therapeutic use in treating psychosis, mental illness, and other central nervous system (CNS) disorders. The abstract indicates the compounds are designed to interact with serotonin receptors, a common target for psychedelic and psychiatric drugs, but provides no experimental data, results, or evidence of efficacy.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Intervention | 3-Cycloaminoindole compounds |
| Key finding | Novel 3-cycloaminoindole compounds are proposed as serotonergic psychedelic agents for treating psychosis, mental illness, and CNS disorders. |
Abstract
Novel 3-Cycloaminoindole Compounds as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.